Ind-Swift Lab.
Ticker > Company >

Ind-Swift Lab. share price

Ind-Swift Laboratories Ltd.

NSE: INDSWFTLAB BSE: 532305 SECTOR: Pharmaceuticals & Drugs  47.94 K   68   12

107.00
-0.26 (-0.24%)
BSE: 12 Sep 04:01 PM

Price Summary

Today's High

₹ 108.7

Today's Low

₹ 105.15

52 Week High

₹ 148.5

52 Week Low

₹ 67.15

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 873.24 Cr.

Enterprise Value

₹ 453.08 Cr.

No. of Shares

8.16 Cr.

P/E

3.78

P/B

0.63

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  171.13

CASH

₹ 425.73 Cr.

DEBT

₹ 5.57 Cr.

Promoter Holding

40.94 %

EPS (TTM)

₹  28.32

Sales Growth

6.54%

ROE

59.2 %

ROCE

55.54%

Profit Growth

885.1 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year6.54%
3 Year12.74%
5 Year11.12%

Profit Growth

1 Year885.1%
3 Year359.67%
5 Year61.08%

ROE%

1 Year59.2%
3 Year22.35%
5 Year12.12%

ROCE %

1 Year55.54%
3 Year25.23%
5 Year17.99%

Debt/Equity

0.006

Price to Cash Flow

-4.86

Interest Cover Ratio

12.3018

CFO/PAT (5 Yr. Avg.)

0.924159116286285

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 40.94 0.00
Mar 2025 40.94 0.00
Dec 2024 42.00 0.00
Sep 2024 42.00 0.00
Jun 2024 42.01 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 359.668021484228% for the Past 3 years.
  • The company has significantly decreased its debt by 838.1009 Cr.
  • Company has been maintaining healthy ROE of 22.3481763289909% over the past 3 years.
  • Company has been maintaining healthy ROCE of 25.2260510348175% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 12.3018.
  • Company’s PEG ratio is 0.00426801123616236.
  • The company has an efficient Cash Conversion Cycle of 9.8327 days.
  • Company has a healthy liquidity position with current ratio of 3.0593.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 14.6724251774773.

 Limitations

  • The company has shown a poor revenue growth of 12.7360483270744% for the Past 3 years.
  • Company has negative cash flow from operations of -179.768.
  • The company is trading at a high EV/EBITDA of 34.3476.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 144.31 2.71 1.41 144.75 148
Total Expenditure 145.58 14.71 10.22 158.21 144.92
Operating Profit -1.27 -12 -8.81 -13.47 3.07
Other Income 43.07 12.95 13.81 4.41 14.58
Interest 9.71 0.41 0.11 -26.76 1.15
Depreciation 5.62 0.22 0.25 7.44 6.68
Exceptional Items 7.96 0 0 215.88 0
Profit Before Tax 34.43 0.32 4.64 226.15 9.83
Tax 0 0 0 8.06 1.71
Profit After Tax 34.43 0.32 4.64 218.09 8.12
Adjusted EPS (Rs) 5.12 0.05 0.78 31.72 1.18

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 751.84 856.58 988.09 1151.96 1227.32
Total Expenditure 610.78 676.1 794.38 929.86 977.35
Operating Profit 141.06 180.48 193.71 222.09 249.97
Other Income 36.08 23.13 42.5 33.28 45.31
Interest 106.65 100.2 95.55 92.17 51.1
Depreciation 90.06 87.29 130.97 57.36 53.3
Exceptional Items 0 0 -1.69 -26.65 386.59
Profit Before Tax -19.56 16.12 8 79.2 577.47
Tax 1.23 20.52 13.7 36.73 159.08
Net Profit -20.79 -4.4 -5.71 42.47 418.39
Adjusted EPS (Rs.) -3.52 -0.74 -0.97 7.19 70.81

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 59.81 59.81 59.81 59.81 59.09
Total Reserves 584.8 578.89 572.75 615.54 863.16
Borrowings 890.89 875.41 839.07 744.43 3
Other N/C liabilities -62.56 -42.46 -32.7 -11.41 -30.61
Current liabilities 309.29 286.72 313.61 350.05 178.32
Total Liabilities 1782.23 1758.36 1752.53 1758.42 1072.95
Assets
Net Block 842.93 737.64 626.79 585 5.32
Capital WIP 3.8 10.7 9.31 7.71 0
Intangible WIP 7.65 8.14 1 0 0
Investments 26.36 55.33 110.68 85.12 165.94
Loans & Advances 56.92 65.97 3.89 4.1 353.84
Other N/C Assets 0 14.77 4.72 3.82 2.3
Current Assets 844.56 865.8 996.15 1072.67 545.54
Total Assets 1782.23 1758.36 1752.53 1758.42 1072.95
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -19.56 16.12 9.69 105.85 190.88
Adjustment 176.02 179.35 225.59 132.78 124.76
Changes in Assets & Liabilities -33.3 -60.43 -99.02 -55.95 -495.41
Tax Paid 0 0 0 0 0
Operating Cash Flow 123.16 135.03 136.26 182.67 -179.77
Investing Cash Flow -10.15 -10.17 2.76 -13.69 -104.32
Financing Cash Flow -133.26 -123.75 -139.59 -168.41 699.86
Net Cash Flow -20.25 1.11 -0.57 0.58 415.77

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 42.01 42.00 42.00 40.94 40.94
essix biosciences limited... 37.79 37.79 37.79 36.83 36.83
gopal munjal 0.10 0.10 0.10 0.10 0.10
himanshu jain 0.69 0.69 0.69 0.67 0.67
late neera mehta 0.42 0.42 0.42 0.41 0.41
meenakshi mehta 0.02 0.02 0.02 0.02 0.02
n.r. munjal 1.56 1.56 1.56 1.52 1.52
neeta munjal 0.02 0.02 0.02 0.02 0.02
nidhi munjal 0.02 0.02 0.02 0.02 0.02
ravi mehta 0.02 0.02 0.02 0.02 0.02
rishav mehta 0.77 0.77 0.77 0.75 0.75
s. r. mehta 0.40 0.40 0.40 0.39 0.39
sahil munjal 0.01 0.01 0.01 0.01 0.01
sunita jain 0.08 0.08 0.08 0.08 0.08
v.r. mehta 0.09 0.09 0.09 0.09 0.09
bhanavi mehta 0.01 0.01 0.01 - -
divya munjal 0.01 0.01 0.01 - -
ishav mehta 0.01 0.01 0.01 - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 57.99 58.00 58.00 59.06 59.06
ashokkumar chandak 3.83 3.83 3.92 3.88 3.99
conquer investment & fina... 1.18 1.18 1.18 1.15 1.15
llp - 0.14 0.25 0.15 0.34
panchkula finvest private... - - - - 1.90
pranav joneja - - - - 1.67
sharwan singh guleria 1.24 1.61 1.61 1.56 1.76
sri ganesh biotech privat... 1.35 1.35 1.35 1.31 1.31
zeal global opportunities... - - - 2.53 2.53
investor education and pr... 0.26 - - 0.25 -
wilson holdings private l... 9.93 9.20 9.19 8.72 -
giriraj ratan damani - 1.09 - - -
investor education and pr... - 0.26 - - -
panjatan real estate priv... - 1.35 - - -
anirudh damani 1.03 - - - -
patanjali real estate pro... 1.07 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
Credit ICRA
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q2FY21

Company News

Ind-Swift Lab. - Quaterly Results 13 Aug, 6:23 PM Ind-Swift Lab. - Quaterly Results 13 Aug, 6:23 PM Ind-Swift Lab. - Quaterly Results 11 Aug, 9:07 PM Ind-Swift Lab. - Quaterly Results 11 Aug, 9:07 PM Ind-Swift Laboratories informs about disclosure 25 Jul, 11:52 AM Ind-Swift Laboratories informs about disclosure 4 Jul, 12:00 PM Ind-Swift Laboratories informs about communication to shareholders 21 Jun, 4:16 PM Ind-Swift Lab. - Quaterly Results 14 Feb, 11:16 AM Ind-Swift Lab. - Quaterly Results 14 Feb, 11:16 AM Ind-Swift Lab. - Quaterly Results 14 Feb, 11:16 AM Ind-Swift Laboratories informs about press release 22 Jan, 2:08 PM IND-Swift Laboratories informs about scheme of arrangement 4 Jan, 5:17 PM Ind-Swift Laboratories purchases land to set up new formulations facility 2 Jan, 10:11 AM Ind-Swift Laboratories acquires land to set up new R&D Centre in Punjab 10 Dec, 10:58 AM Ind-Swift Lab. - Quaterly Results 11 Nov, 6:59 PM Ind-Swift Lab. - Quaterly Results 11 Nov, 6:59 PM IND-Swift Laboratories informs about press release 23 Sep, 11:43 AM Ind-Swift Laboratories sets up new marketing office in New Delhi 23 Sep, 11:19 AM Ind-Swift Lab. - Quaterly Results 12 Aug, 7:44 PM Ind-Swift Lab. - Quaterly Results 12 Aug, 7:44 PM Ind-Swift Laboratories incorporates wholly owned subsidiary in UAE 20 May, 12:12 PM Ind-Swift Lab. - Quaterly Results 13 May, 7:47 PM Ind-Swift Lab. - Quaterly Results 13 May, 7:47 PM Ind-Swift Laboratories to incorporate wholly owned subsidiary in UAE 19 Apr, 12:15 PM Ind-Swift Laboratories informs about acquisition 19 Apr, 11:29 AM Ind-Swift Laboratories informs about disclosure 4 Apr, 10:02 AM Ind-Swift Laboratories informs about disclosure 3 Apr, 5:01 PM Ind-Swift Laboratories informs about disclosure 3 Apr, 12:15 PM Ind-Swift Laboratories informs about disclosure 30 Mar, 3:31 PM Ind-Swift Laboratories informs about disclosure 28 Mar, 10:58 AM Ind-Swift Lab. - Quaterly Results 12 Feb, 4:58 PM Ind-Swift Lab. - Quaterly Results 12 Feb, 4:58 PM Ind-Swift Lab. - Quaterly Results 12 Feb, 4:58 PM Ind-Swift Laboratories informs about disclosure 8 Feb, 2:51 PM Ind-Swift Laboratories collaborates with CSIR- IMTECH 30 Nov, 9:36 AM Ind-Swift Laboratories informs about outcome of board meeting 7 Nov, 5:18 PM Ind-Swift Laboratories informs about outcome of board meeting 7 Nov, 5:01 PM Ind-Swift Lab. - Quaterly Results 7 Nov, 4:13 PM Ind-Swift Lab. - Quaterly Results 7 Nov, 4:13 PM Ind-Swift Laboratories gets nod to sell API Business to Synthimed Labs 6 Sep, 2:30 PM Ind-Swift Laboratories informs about outcome of board meeting 31 Aug, 5:00 PM Ind-Swift Lab. - Quaterly Results 9 Aug, 7:17 PM Ind-Swift Lab. - Quaterly Results 9 Aug, 7:17 PM Ind-Swift Laboratories informs about interest payment 22 Jun, 1:30 PM Ind-Swift Laboratories informs about updates 1 Jun, 2:28 PM Ind-Swift Lab. - Quaterly Results 29 May, 6:46 PM Ind-Swift Laboratories gets nod to sell M/s. Halcyon life Sciences 31 Mar, 10:29 AM Ind-Swift Lab. - Quaterly Results 14 Feb, 5:35 PM Ind-Swift Laboratories wins ‘Asia's best Company for the year 2022’ award 27 Dec, 2:58 PM Ind-Swift Laboratories informs about loss of original share certificate 10 Nov, 12:41 PM

Ind-Swift Lab. Stock Price Analysis and Quick Research Report. Is Ind-Swift Lab. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Ind-Swift Lab.. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Ind-Swift Lab. has a PE ratio of 3.73063982573637 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Ind-Swift Lab. has ROA of 29.5539% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Ind-Swift Lab. has a Current ratio of 3.0593.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Ind-Swift Lab. has a ROE of 59.2007%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Ind-Swift Lab. has a Debt to Equity ratio of 0.006 which means that the company has low proportion of debt in its capital.

  • Sales growth: Ind-Swift Lab. has reported revenue growth of 6.542% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Ind-Swift Lab. for the current financial year is 20.3668405417341%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Ind-Swift Lab. is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Ind-Swift Lab. is Rs 28.3249. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Ind-Swift Lab. in Ticker for free. Also, one can get the intrinsic value of Ind-Swift Lab. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Ind-Swift Lab. FAQs

Q1. What is Ind-Swift Lab. share price today?
Ans: The current share price of Ind-Swift Lab. is Rs 105.67.

Q2. What is the market capitalisation of Ind-Swift Lab.?
Ans: Ind-Swift Lab. has a market capitalisation of Rs 862.389333386 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Ind-Swift Lab.?
Ans: The PE ratio of Ind-Swift Lab. is 3.73063982573637 and the P/B ratio of Ind-Swift Lab. is 0.617472959627892, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Ind-Swift Lab. share?
Ans: The 52-week high share price of Ind-Swift Lab. is Rs 148.9, and the 52-week low share price of Ind-Swift Lab. is Rs 68.72.

Q5. Does Ind-Swift Lab. pay dividends?
Ans: Currently, Ind-Swift Lab. does not pay dividends. Dividend yield of Ind-Swift Lab. is around 0%.

Q6. What are the face value and book value of Ind-Swift Lab. shares?
Ans: The face value of Ind-Swift Lab. shares is Rs 10, while the book value per share of Ind-Swift Lab. is around Rs 171.133. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Ind-Swift Lab.?
Ans: Ind-Swift Lab. has a total debt of Rs 5.5664 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Ind-Swift Lab.?
Ans: The ROE of Ind-Swift Lab. is 59.2007% and ROCE of Ind-Swift Lab. is 55.5414%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Ind-Swift Lab. a good buy for the long term?
Ans: The Ind-Swift Lab. long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Ind-Swift Lab. undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Ind-Swift Lab. appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Ind-Swift Lab.’s financials?
Ans: You can review Ind-Swift Lab.’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Ind-Swift Lab.
X